It's time to reimagine reimbursement for CAR T-cell therapy
The American Journal of Managed Care · 01.12.2025 · 31 (Spec. No. 13) · SP922
DOI: 10.37765/ajmc.2025.89878 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Journal of Managed Care, online erschienen am 02.12.2025. Verfasst von Anna Sureda und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Insurance, Health, Reimbursement, Immunotherapy, Adoptive, Reimbursement Mechanisms. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Zitieren
APA
Sureda, A., O'Neill, M., & O'Rourke, B. (2025). It's time to reimagine reimbursement for CAR T-cell therapy. The American Journal of Managed Care, 31(Spec. No. 13), SP922. https://doi.org/10.37765/ajmc.2025.89878
Vancouver
Sureda A, O'Neill M, O'Rourke B. It's time to reimagine reimbursement for CAR T-cell therapy. The American Journal of Managed Care. 2025;31(Spec. No. 13):SP922. doi:10.37765/ajmc.2025.89878
BibTeX
@article{Sureda2025,
author = {Sureda, Anna and O'Neill, Meagan and O'Rourke, Brian},
title = {It's time to reimagine reimbursement for CAR T-cell therapy},
journal = {The American Journal of Managed Care},
year = {2025},
volume = {31},
number = {Spec. No. 13},
pages = {SP922},
doi = {10.37765/ajmc.2025.89878}
}
EUVIMED